{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=61", "query": { "condition": "Carcinoma, Bronchogenic", "page": 61 }, "page_size": 10 }, "pagination": { "page": 61, "page_size": 10, "total_count": 3591, "total_pages": 360, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=62&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=60&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T04:26:09.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05168566", "title": "Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Sutetinib Maleate Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teligene US", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2022-09-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 8, "location_summary": "Glendale, California • Washington D.C., District of Columbia • Athens, Georgia + 5 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Athens", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05168566" }, { "nct_id": "NCT00509366", "title": "Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin & Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin & Pemetrexed", "type": "DRUG" }, { "name": "Docetaxel & Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed & Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2007-05", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-08-28", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 8, "location_summary": "Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509366" }, { "nct_id": "NCT04300556", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Farletuzumab ecteribulin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-08-06", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 24, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300556" }, { "nct_id": "NCT03090737", "title": "Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-06-02", "completion_date": "2022-03-14", "has_results": true, "last_update_posted_date": "2022-12-05", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Billings, Montana + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Billings", "state": "Montana" }, { "city": "Johnson City", "state": "New York" }, { "city": "Sayre", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03090737" }, { "nct_id": "NCT00365183", "title": "Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Motexafin gadolinium and pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2006-06", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2013-10-31", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 11, "location_summary": "Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365183" }, { "nct_id": "NCT04772053", "title": "Molecular Disease Characterization Initiative (MDCI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Non-Small Cell", "Neoplasms" ], "interventions": [ { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-05-25", "completion_date": "2022-11-15", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772053" }, { "nct_id": "NCT04681131", "title": "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "CAB-AXL-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2021-03-17", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 32, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 26 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681131" }, { "nct_id": "NCT00003037", "title": "Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-04", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2013-06-27", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003037" }, { "nct_id": "NCT03923777", "title": "Active Surveillance in Early Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IA Non-small Cell Lung Cancer", "Lung Carcinoid Tumor" ], "interventions": [ { "name": "Active Surveillance", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Vermont Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 26, "start_date": "2018-07-31", "completion_date": "2022-07", "has_results": false, "last_update_posted_date": "2020-07-16", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT03923777" }, { "nct_id": "NCT02460367", "title": "Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Progression of Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Tergenpumatucel-L", "type": "BIOLOGICAL" }, { "name": "Indoximod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-01", "completion_date": "2021-01-13", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-10-26T04:26:09.222Z", "location_count": 2, "location_summary": "St Louis, Missouri • Cincinnati, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02460367" } ] }